Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
Status: Recruiting
Location: See all (6) locations...
Study Type: Observational
SUMMARY
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:
• Age ≤ 18 years at time of transplant listing
• Subject is within 10-50 days post-orthotopic heart transplant at time of enrollment.
• Planned follow-up at the transplant center for a minimum of one-year.
• Caregiver able and willing to comply with the study visit schedule, study procedures, and study requirements.
Locations
United States
Colorado
Children's Hospital Colorado
RECRUITING
Aurora
New York
Columbia University
RECRUITING
New York
Pennsylvania
University of Pittsburgh
RECRUITING
Pittsburgh
Tennessee
Monroe Carell Jr. Children's Hospital at Vanderbilt
RECRUITING
Nashville
Texas
Texas Children's Hospital
RECRUITING
Houston
Virginia
Inova Health System
NOT_YET_RECRUITING
Falls Church
Contact Information
Primary
Palak Shah, MD
palak.shah@inova.org
(703) 776-8000
Backup
Michaela Ramandanes, MPH
michaela.ramandanes@inova.org
(703) 776-6466
Time Frame
Start Date: 2025-02-06
Estimated Completion Date: 2029-10-01
Participants
Target number of participants: 150
Related Therapeutic Areas
Sponsors
Leads: Inova Health Care Services